Oyster Point Pharma to Participate in the Piper Sandler 33rd Annual Healthcare Conference
Oyster Point Pharma (Nasdaq: OYST) will participate virtually in the Piper Sandler 33rd Annual Healthcare Conference on December 2, 2021. The biopharmaceutical company focuses on developing therapies for ophthalmic diseases. Recently, in October 2021, Oyster Point received FDA approval for TYRVAYA™ Nasal Spray to treat dry eye disease. The company is expanding its research pipeline through internal innovations and collaborations, aiming to address unmet patient needs in eye care.
- None.
- None.
PRINCETON, N.J., Nov. 30, 2021 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ophthalmic diseases, today announced that the Company will participate virtually in the Piper Sandler 33rd Annual Healthcare Conference on Thursday, December 2, 2021. Presentations are available for registered attendees via the Piper Sandler conference site
About Oyster Point Pharma, Inc.
Oyster Point Pharma is a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ophthalmic diseases. In October 2021, Oyster Point Pharma received FDA approval for TYRVAYA™ (varenicline solution) Nasal Spray for the treatment of the signs and symptoms of dry eye disease. Oyster Point has a growing pipeline of clinical and pre-clinical programs and continues to expand its research and development pipeline through internal innovation and external collaborations. Oyster Point is continuously striving to advance breakthrough science and deliver therapies seeking to address the unmet needs of patients with ophthalmic disease and the eye care professionals who take care of them. For more information, visit www.oysterpointrx.com and follow @OysterPointRx on Twitter and LinkedIn.
Investor Contact:
Tim McCarthy
LifeSci Advisors, LLC
(212) 915-2564
investors@oysterpointrx.com
Media Contact:
Sheryl Seapy
Real Chemistry
(213) 262-9390
sseapy@realchemistry.com
FAQ
When is Oyster Point Pharma participating in the Piper Sandler Healthcare Conference?
What recent FDA approval did Oyster Point Pharma receive?
What is Oyster Point Pharma's focus area?
How is Oyster Point Pharma expanding its research pipeline?
What stock symbol does Oyster Point Pharma trade under?
